Intervention not reported
Anthropometric outcomes: MUAC gain per day Defined as (discharge MUAC − admission MUAC)/days in treatment among children with no oedema and discharged as cured (Charle‐Cuellar 2021)c · children aged > 6 months and < 5 years with wasting
1 finding from 1 review
Intervention not reported
Anthropometric outcomes: mean weight gain per day (g/kg/d) Defined as ((discharge weight − admission weight)/admission weight)/days in treatment (Wilunda 2021)e · children aged > 6 months and < 5 years with wasting
1 finding from 1 review
Intervention not reported
Anthropometric outcomes: median weight gain per day (g/kg/d) Defined as ((discharge weight − admission weight)/weight on admission)/days on treatment among children with no oedema and discharged as cured (Charle‐Cuellar 2021)c · children aged > 6 months and < 5 years with wasting
1 finding from 1 review
Intervention not reported
Transfer to inpatient care Defined as referral for: presence of danger signs and failed appetite test on first day of treatment (Alvarez Moran 2018)b; appearance of severe signs of illness, persistent oedema, absence of weight gain in non‐oedemato... · children aged > 6 months and < 5 years with wasting
It is very uncertain whether the intervention changes transfer to inpatient care Defined as referral for: presence of… (very low certainty).
1 finding from 1 review
Intervention not reported
Anthropometric outcomes: weight gain per day (g/kg/day) Calculated as ((discharge weight − admission weight)/weight on admission)/days in treatment among recovered children (Hussain 2021) · children aged > 6 months and ≤ 5 years with wasting
1 finding from 1 review
Intervention not reported
All‐cause mortality at day 28 · unvaccinated, non‐hospitalized people with mild symptomatic COVID‐19 (WHO scale 2 to 3) at high risk for progression to severe disease
The intervention may leads to lower all‐cause mortality at day 28 (low certainty).
1 finding from 1 review
Intervention not reported
Viral clearance at 14 days · unvaccinated, non‐hospitalized people with mild symptomatic COVID‐19 (WHO scale 2 to 3) at high risk for progression to severe disease
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Intervention not reported
All‐cause mortality at day 28 · hospitalized people with mild to moderate symptomatic COVID‐19 (WHO scale 2 to 4) with severe comorbidities
It is very uncertain whether the intervention changes all‐cause mortality at day 28 (very low certainty).
1 finding from 1 review
Intervention not reported
Quality of life up to 28 days and longest · hospitalized people with mild to moderate symptomatic COVID‐19 (WHO scale 2 to 4) with severe comorbidities
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Intervention not reported
Viral clearance at 7 days · hospitalized people with mild to moderate symptomatic COVID‐19 (WHO scale 2 to 4) with severe comorbidities
It is very uncertain whether the intervention changes viral clearance at 7 days (very low certainty).
1 finding from 1 review
Intervention not reported
Viral clearance at 14 days · hospitalized people with mild to moderate symptomatic COVID‐19 (WHO scale 2 to 4) with severe comorbidities
It is very uncertain whether the intervention changes viral clearance at 14 days (very low certainty).
1 finding from 1 review
Intervention not reported
All initial symptoms resolved at 28 days, and up to the longest · unvaccinated, non‐hospitalized people with mild symptomatic COVID‐19 (WHO scale 2 to 3) at high risk for progression to severe disease
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Intervention not reported
Quality of life up to 28 days and longest · unvaccinated, non‐hospitalized people with mild symptomatic COVID‐19 (WHO scale 2 to 3) at high risk for progression to severe disease
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Bronchopulmonary dysplasia/chronic lung disease · preterm infants
Caffeine showed no clear difference in bronchopulmonary dysplasia/chronic lung disease: defined as 28 days… compared with other methylxanthines (low certainty).
1 finding from 1 review
RR 1.4 [0.92, 2.11]
Studies not reported
Low
Length of hospital stay · preterm infants
1 finding from 1 review
no estimate extracted
Studies not reported
Low
Rate of orthodontic tooth movement during space closure stage (maxillary canine distalisation), mm/day · Adolescents and adults with malocclusion undergoing fixed orthodontic appliance treatment
It is very uncertain whether light-emitting diode (LED) photobiomodulation changes rate of orthodontic tooth movement during space closure stage… compared with conventional orthodontic appliance treatment (very low certainty).
1 finding from 1 review
Mean time to resolution of pain · Adults (>18 years) with established dry socket following permanent tooth extraction
Neocone led to lower time to complete resolution of pain (days) compared with alvogyl; GRADE not reported.
1 finding from 1 review
Mean time to resolution of pain · Adults (>18 years) with established dry socket following permanent tooth extraction
Alvogyl led to lower time to complete resolution of pain (days) compared with zinc oxide eugenol; GRADE not reported.
1 finding from 1 review
Duration of treatment (days) · Adults (>18 years) with established dry socket following permanent tooth extraction
Metronidazole (intrasocket) led to lower duration of treatment (days) compared with placebo; GRADE not reported.
1 finding from 1 review
Mean time to resolution of pain · Adults (>18 years) with established dry socket following permanent tooth extraction
Neocone led to lower time to complete resolution of pain (days) compared with zinc oxide eugenol; GRADE not reported.
1 finding from 1 review